---
figid: PMC3342058__fimmu-03-00036-g002
figtitle: Major therapeutic targets for inhibition of donor-reactive memory T cell
  responses
organisms:
- NA
pmcid: PMC3342058
filename: fimmu-03-00036-g002.jpg
figlink: /pmc/articles/PMC3342058/figure/F2/
number: F2
caption: Major therapeutic targets for inhibition of donor-reactive memory T cell
  responses. Transplantation therapeutics have been developed that target memory T
  cell costimulation pathways, intracellular signaling pathways, and trafficking molecules.
  Alemtuzumab, anti-CD52 monoclonal antibody. Alefacept, LFA-3 Ig fusion protein.
  Belatacept, high-affinity CTLA-4 Ig fusion protein. Anti-OX40L mAb, anti-OX40 ligand
  monoclonal antibody. Efalizumab, anti-LFA-1 monoclonal antibody. Natalizumab, anti-VLA-4
  monoclonal antibody. Sirolimus, Mammalian Target of Rapamycin (mTOR) pathway inhibitor.
  Tacrolimus, Calcineurin A (CnA)-NFAT pathway inhibitor. Oxelumab, anti-OX40 monoclonal
  antibody. Bortezomib, protease inhibitor. Gray box, FDA approved therapeutic. Blue
  box, experimental therapeutic under clinical development.
papertitle: 'Heterogeneity within T Cell Memory: Implications for Transplant Tolerance.'
reftext: Scott M. Krummey, et al. Front Immunol. 2012;3:36.
year: '2012'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8089928
figid_alias: PMC3342058__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC3342058__F2
ndex: 7c07999a-df28-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3342058__fimmu-03-00036-g002.html
  '@type': Dataset
  description: Major therapeutic targets for inhibition of donor-reactive memory T
    cell responses. Transplantation therapeutics have been developed that target memory
    T cell costimulation pathways, intracellular signaling pathways, and trafficking
    molecules. Alemtuzumab, anti-CD52 monoclonal antibody. Alefacept, LFA-3 Ig fusion
    protein. Belatacept, high-affinity CTLA-4 Ig fusion protein. Anti-OX40L mAb, anti-OX40
    ligand monoclonal antibody. Efalizumab, anti-LFA-1 monoclonal antibody. Natalizumab,
    anti-VLA-4 monoclonal antibody. Sirolimus, Mammalian Target of Rapamycin (mTOR)
    pathway inhibitor. Tacrolimus, Calcineurin A (CnA)-NFAT pathway inhibitor. Oxelumab,
    anti-OX40 monoclonal antibody. Bortezomib, protease inhibitor. Gray box, FDA approved
    therapeutic. Blue box, experimental therapeutic under clinical development.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD52
  - CD27
  - CD70
  - CD58
  - CD28
  - CD80
  - CTLA4
  - MTOR
  - CD86
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - TNFRSF4
  - TNFSF4
  - ICOS
  - ICOSLG
  - ITGAL
  - ITGB2
  - Tacrolimus
  - Sirolimus
---
